Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Biology

Cancer Oncology

Medicine

Immunology

Paleontology

Show all topics

DOI

10.1200/jco.20.02110

License

CC-BY-NC-ND

Other Formats

PDF